Clinical Factors Affecting the Dose Conversion Ratio from Intravenous to Oral Tacrolimus Formulation among Pediatric Hematopoietic Stem Cell Transplantation Recipients

Conclusions: After switching of tacrolimus formulation, pediatric HCT recipients might need oral tacrolimus dose that is 5–6 and 3.5–4.5 times the intravenous dose to maintain tacrolimus blood concentrations and area under the concentration–time curve, respectively. With the concomitant use of voriconazole or itraconazole, an oral tacrolimus dose of 4–5 times the intravenous dose seemed appropriate to maintain blood tacrolimus concentration.
Source: Therapeutic Drug Monitoring - Category: Drugs & Pharmacology Tags: Original Article Source Type: research